Skip to content
★ Sign in to follow
RA

Renée Aguiar Lucander

Calliditas Therapeutics AB
Total declarations
19
Company
1
▲ Purchases (6 ops.)
€297k
▼ Sales (3 ops.)
€14.8M

Latest filing published 04 Sept 2024 for Calliditas Therapeutics AB, €13.5M.

Filing timeline

BuySale
Renée Aguiar Lucander

Insider track record

Disclosed buys
6
Disclosed sells
3
Signal history

Closed purchases

Market purchases
6

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

Renée Aguiar Lucander: trading record in brief

Renée Aguiar Lucander discloses dealings in Calliditas Therapeutics AB to Finansinspektionen. We count 19 filings; the first trade dates from 19 December 2018 and the latest from 2 September 2024.

Both buying and selling appear: 6 purchases worth €297k, against 3 sales worth €14.8M. The amount is not disclosed for 2 filings. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. 2024 to date brings 2 purchases and 1 sale.

A typical purchase (the median) is worth €68k.

The latest filing, published on 4 September 2024, reports an open-market sale of €13.5M in Calliditas Therapeutics AB. The most recent open-market purchase was published on 4 July 2024, 857 days ago. Between a trade and the moment it shows up on Finansinspektionen, the median delay is 3 days. Under the Market Abuse Regulation, managers have three business days to notify their trades. These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.

Companies and markets linked to Renée Aguiar Lucander

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations19 total

19 of 19 declarations